ec23

Retinoic acid receptor ligand



BML-EC23-0500	5 mg	65.00 USD

BML-EC23-2500	25 mg	281.00 USD

All-Trans Retinoic Acid (ATRA; Prod. No. BML-GR100) is often employed in cell culture to induce stem cell differentiation or enhance the growth, differentiation and maintenance of neural cell types. It is frequently included as a component of many commercially available culture supplements. Whilst it is a well-used differentiating agent, ATRA is unstable and exposure to light and other factors such as temperature and oxidation render the molecule susceptible to isomerisation, leading to molecular degradation into a mixture of retinoid isomers.

more

Product Specification

Alternative Name:	4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylethynyl) benzoic acid

Formula:	C₂₃H₂₄O₂

MW:	332.0

Purity:	≥99% (HPLC)

Appearance:	White to off-white lyophilised amorphous solid.

CAS:	104561-41-3

Source/Host:	Synthetic.

Solubility:	Soluble in DMSO (10mg/ml). Limited solubility in water or 95% ethanol (0.33mg/ml); vortex to dissolve.

Long Term Storage:	+20°C

Use/Stability:	Stock solutions are stable at room temperature for long periods without the need to protect from light or store under inert gas. Storage at 4ºC is not likely to reduce efficacy. Dilutions from the stock solution can be made in aqueous media, including cell culture growth media. ec23 is effective over a broad range of concentrations, but typically within the range 100nM-10µM when used on cells in culture.

Hazard:	MAY BE TERATOGENIC. TOXIC.

Background / Technical Information:	Dilutions from the stock solution (see SOLUBILITY above) can be made in aqueous media, including cell culture growth media. ec23 is effective over a broad range of concentrations, but typically within the range 100nM-10µM when used on cells in culture. ec23 is manufactured and packaged by the patent holder (Reinnervate Ltd, UK). The ec23 device is a trademark of Reinnervate Ltd. Enzo Life Sciences has a worldwide licence to distribute ec23 for research use only.